# Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation

> **NCT02227641** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 50 (actual)

## Conditions studied

- Patients Undergoing Allogeneic Stem Cell Transplantation

## Interventions

- **BIOLOGICAL:** CMV/EBV specific T-cell

## Key facts

- **NCT ID:** NCT02227641
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2016-10
- **Final completion:** 2017-03
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-12-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02227641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02227641, "Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02227641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*